@ARTICLE{
author={Rodriguez-Abreu Delvys,...,Secen Nevena M,...,(broj koautora 21)},
year={2020},
title={Randomized, double-blind, phase II study of tiragolumab plus atezolizumab versus placebo plus atezolizumab as first-line treatment for PD-L1-selected NSCLC (CITYSCAPE)},
journal={SWISS MEDICAL WEEKLY},
volume={},
number={},
pages={31S-31S},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Rodriguez-Abreu Delvys,...,Secen Nevena M,...,(broj koautora 20)},
year={2020},
title={Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={38},
number={15},
pages={-},
document_type={Meeting Abstract},
}